MARKET

FBLG

FBLG

Fibrobiologics
NASDAQ
0.9213
-0.0287
-3.02%
Opening 14:07 10/26 EDT
OPEN
0.9300
PREV CLOSE
0.9500
HIGH
0.9498
LOW
0.8900
VOLUME
139.13K
TURNOVER
--
52 WEEK HIGH
9.60
52 WEEK LOW
0.6201
MARKET CAP
6.13M
P/E (TTM)
-0.1604
1D
5D
1M
3M
1Y
5Y
1D
FibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease Model
Benzinga · 10/19 12:34
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
PR Newswire · 10/19 12:30
Weekly Report: what happened at FBLG last week (1012-1016)?
Weekly Report · 10/19 09:40
FibroBiologics’ patent application accepted in Australia
TipRanks · 10/14 12:40
FibroBiologics Says IP Australia Issues Notice Of Acceptance For Australian Patent Application Titled ‘Cellular Blend For The Regeneration Of Chondrocytes Or Cartilage Type Cells’
Benzinga · 10/14 12:35
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/13 21:06
Weekly Report: what happened at FBLG last week (1005-1009)?
Weekly Report · 10/12 09:42
FibroBiologics Raises Capital via Convertible Debenture Financing
TipRanks · 10/08 21:49
More
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).

Webull offers Fibrobiologics Inc stock information, including NASDAQ: FBLG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBLG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FBLG stock methods without spending real money on the virtual paper trading platform.